 | |
| Type | Public |
|---|---|
| Industry | Healthcare |
| Founded | 2005 |
| Headquarters | Boston, United States |
Key people | Christopher Viehbacher (Chairman) Daphne Zohar (CEO) |
| Products | Medicines |
| Revenue |  $15.6 million (2022) [1] |
| $(197.8) million (2022) [1] | |
 $(37.4) million (2022) [1] | |
| Website | puretechhealth |
PureTech Health is a biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
The company was founded by Daphne Zohar, an American entrepreneur, in 2005. [2] It was the subject of an initial public offering on the London Stock Exchange in June 2015. [3]
Companies which PureTech Health founded include Karuna Pharmaceuticals, [4] Gelesis, which has received FDA approval as a treatment for weight management, [5] Akili Interactive Labs, which is developing a digital therapeutic platform for cognitive disorders, [6] Vedanta Biosciences, which is developing drugs to treat autoimmune and inflammatory diseases, [7] and Follica which is developing new treatments for androgentic alopecia among others. [8] PureTech also has a pipeline of its own immunology, lymphatic and oncology based therapeutics. [9]
Gregory Stock is an American biophysicist, best-selling author, biotech entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA’s School of Medicine. His interests lie in the scientific and evolutionary as well as ethical, social and political implications of today's revolutions in the life sciences and in information technology and computers.
Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index. Celltech was instrumental in changing the UK's system of technology transfer from research to business, and in creating the biotechnology industry.
Lymphatic filariasis is a human disease caused by parasitic worms known as filarial worms. Usually acquired in childhood, it is a leading cause of permanent disability worldwide. While most cases have no symptoms, some people develop a syndrome called elephantiasis, which is marked by severe swelling in the arms, legs, breasts, or genitals. The skin may become thicker as well, and the condition may become painful. Affected people are often unable to work and are often shunned or rejected by others because of their disfigurement and disability.
Neglected tropical diseases (NTDs) are a diverse group of tropical infections that are common in low-income populations in developing regions of Africa, Asia, and the Americas. They are caused by a variety of pathogens, such as viruses, bacteria, protozoa, and parasitic worms (helminths). These diseases are contrasted with the "big three" infectious diseases, which generally receive greater treatment and research funding. In sub-Saharan Africa, the effect of neglected tropical diseases as a group is comparable to that of malaria and tuberculosis. NTD co-infection can also make HIV/AIDS and tuberculosis more deadly.
Sir Christopher Thomas Evans is a Welsh professor, scientist and biotechnology entrepreneur. Evans is known for founding and co-founding numerous successful biotech companies in the United Kingdom.
Dr. Hanumappa Sudarshan is an Indian social worker and tribal rights activist. He is known for his contributions to the upliftment of the forest dwelling tribes in the Chamarajanagar district of Karnataka. He is also a recipient of the Right Livelihood Award and the Padma Shri.
Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.
Mark R. Dybul is an American diplomat, physician and medical researcher. He served as the executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2012 until 2017. Since 2021, he has been the CEO of Renovaro Biosciences. Since 2022, he is the Executive Chairman of Purpose Life Sciences.
WuXi AppTec is a global pharmaceutical, biopharmaceutical, and medical device company.
BB Biotech AG is a Swiss investment company in the field of biotechnology. Since 1993 it is listed on the SIX Swiss Exchange, since 1997 on the German TecDAX and from 2000 to 2023 on the Italian Borsa Italiana. The company invests mainly in the United States and Western Europe and is managed by Bellevue Asset Management, a division of Bellevue Group which accounts for approximately 40% of the Group's assets under management.
Actelion is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland.
Cepheid is an American molecular diagnostics company that is a wholly owned subsidiary of Danaher Corporation. Its systems automate traditional nucleic acid tests. The tests can be used to identify and analyze pathogens and genetic disorders. Cepheid sells clinical tests for healthcare-associated infections, infectious diseases, sexual health, oncology and genetics.
BioMotiv is an accelerator company associated with The Harrington Project, an initiative centered at University Hospitals of Cleveland. Therapeutic opportunities were identified through relationships with The Harrington Discovery Institute, university and research institutions, disease foundations, and industry sources. Once opportunities are identified, BioMotiv oversees the development, funding, active management, and partnering of the therapeutic products.
Gelesis is a biotechnology company located in Boston, Massachusetts that developed the weight loss device Gelesis100 (Plenity) for use in overweight and obesity. The company produces Gelesis100, which is a superabsorbent hydrogel capsule that expands in the stomach, creating a feeling of fullness, helping people reduce the amount of food they eat. The company was founded in 2006 to develop medical devices and treatments for obesity.
Signum Biosciences, Inc. is a dietary supplement company located in Boulder, Colorado.
The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID).
Roivant is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies, founded by Vivek Ramaswamy.
Foresite Capital is an American venture capital and growth equity firm headquartered in San Francisco. As of March 2021, the company had raised four funds: Foresite Capital Fund I, II, III, IV and V.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.
